NCT01455844已完成2 期
A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 387
- 试验地点
- 35
- 主要终点
- Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.
研究概览
简要总结
The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for 12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high hypertriglyceridemia as compared to a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female adults aged 18 to 75 years.
- •Fasting plasma levels of TG ≥ 2.28 and <10 mmol/L (200 and 877 mg/dL) on two occasions within 2 weeks (screening and pre-randomization visits).
- •Patients who are currently not on pharmacotherapy for hyperlipidemia and according to the judgement of the physician and Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia initiation of drug therapy is not indicated for the duration of the study.
- •Patients currently treated with statins and according to the judgement of the physician and the Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia a change in their current drug regimen is not indicated for the duration of the study.
- •Patients treated with statin must be on stable dose for at least 6 weeks prior to screening.
- •Patients are willing follow the NCEP Step 1 Diet (see Appendix 4) for the duration of the study.
- •Female participants of childbearing potential (i.e. not surgically sterilized or post-menopausal greater than one year) must have negative serum pregnancy test and must be using an effective birth control method, defined as:
- •continuous use of oral or long acting injected contraceptive for at least 2 months prior to study entry, or;
- •use of an intra-uterine device or implantable contraceptive, or;
- •use of double barrier methods of birth control
- •Patients are at least 80% compliant with the study medication during the placebo lead in phase.
排除标准
- •Any concomitant medication which in the opinion of the investigator would preclude the patient from successfully participating in the study.
- •Women who are pregnant or that are breast feeding.
- •Participation in another clinical trial within 30 days from initiation of the study.
- •Participants with a high risk for cardiovascular disease; (The definition of high-risk individuals will follow that of the 2009 Canadian Guidelines and include a) FRS >= 20% 10-year risk; b) All patients with uncontrolled diabetes (DCA guidelines) and c) Evidence of atherosclerosis -when this evidence was ascertained when clinically indicated);
- •Systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg. In diabetic patients, systolic blood pressure > 130 mmHg and/or diastolic blood pressure > 90 mmHg.
- •History of stroke, intermittent claudication or transient ischemic attack.
- •Known unstable (uncontrolled) cardiac disease , within the last 6 months.
- •Patient with a clinically significant abnormal ECG at screening.
- •Patients with uncontrolled diabetes mellitus, with HbA1c > 7.0%.
- •Known diagnosis of hypoglycemia.
- •Evidence of active renal disease indicated by a fasting estimated glomerular filtration rate (eGFR) of < 60 ml/min per 1.73 m
- •Increased plasma levels (>ULN) of amylase (as per respective lab upper limits) and / or lipase (>160 IU/L) or any indication of pancreatitis pancreatitis (increased alcohol consumption, gallstones).
- •History of pancreatitis.
- •Use of any lipid lowering medication other than statins or ezetimibe(e.g niacin, fibrates) and/or lipid lowering NHP within 6 weeks prior to the screening visit.
- •Intake of > 2 servings per week of fish or regimented use of fish oil/omega-3 supplements within 6 weeks prior to the screening visit.
- •Known HIV or Hepatitis B or C positive.
- •Patients with uncontrolled asthma as defined by the 2010 Consensus Summary of the Canadian Thoracic Society.
- •Known seafood allergy or allergy to any of the medicinal or non-medicinal ingredients of the study medication and placebo, including:
- •Omega-3 fatty acids (including EPA and DHA)
- •Phospholipids (mainly phosphatidylcholine)
- •Astaxanthin
- •Microcrystalline cellulose
- •Coagulopathy or on anticoagulants. Platelet aggregation inhibitors (such as aspirin or clopidogrel but not heparin) are permitted in the study; patients taking both aspirin and clopidogrel are not permitted in the study.
- •Unable or unwilling to comply with the protocol.
- •Patient reported weight was not stable for the past 6 months (within 3kg variation).
- •Consumption of more than 14 standard alcoholic drinks a week.
研究组 & 干预措施
CaPre 1.0g
Experimental
干预措施: CaPre (TM) (Drug)
CaPre 2.0g
Experimental
干预措施: CaPre (TM) (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Other)
结局指标
主要结局
Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.
时间窗: 12 weeks
次要结局
- Absolute change in triglycerides between the baseline and the 12-week assessment visit.(12 weeks)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia RepairIleusNCT00528970Bausch Health Americas, Inc.374
已完成
1 期
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943ObesityNCT06313528Eli Lilly and Company85
已完成
不适用
Assessment of the Efficacy of Andrographis Paniculata in Subjects With Mild to Moderate OsteoarthritisKnee OsteoarthritisNCT03262792Vedic Lifesciences Pvt. Ltd.108
终止
3 期
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneRelapsing-remitting Multiple Sclerosis (RRMS)NCT01633112Novartis Pharmaceuticals1,064
已完成
2 期
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of SchizophreniaSchizophreniaNCT00265551Wyeth is now a wholly owned subsidiary of Pfizer300